Employees: 03 (2023.0)Legal category: 5785Size: PMECreation date: 1988-07-27 (37 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: PONTACQ (64530), Pyrenees-Atlantiques
PHARMACIE DES TILLEULS : revenue, balance sheet and financial ratios
PHARMACIE DES TILLEULS is a French company
founded 37 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in PONTACQ (64530),
this company of category PME
shows in 2023 a revenue of 2.7 M€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - PHARMACIE DES TILLEULS (SIREN 348243734)
Indicator
2024
2023
2022
2021
2020
2019
2018
2017
2016
Revenue
N/C
2 653 986 €
2 124 262 €
N/C
N/C
N/C
1 848 030 €
1 791 051 €
1 788 538 €
Net income
88 777 €
66 420 €
249 936 €
245 569 €
176 545 €
181 584 €
167 837 €
149 734 €
118 289 €
EBITDA
N/C
109 346 €
336 466 €
N/C
N/C
N/C
238 287 €
225 398 €
215 391 €
Net margin
N/C
2.5%
11.8%
N/C
N/C
N/C
9.1%
8.4%
6.6%
Revenue and income statement
In 2024, PHARMACIE DES TILLEULS generates positive net income of 89 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2016-2024: 118 k€ -> 89 k€.
Net income (2024)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
88 777 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 19%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 73%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
Debt ratio (2024)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
18.83%
Financial autonomy (2024)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
73.498%
Asset age ratio (2024)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Solvency indicators evolution PHARMACIE DES TILLEULS
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2016
2017
2018
2019
2020
2021
2022
2023
2024
Debt ratio
81.767
71.644
52.778
45.433
38.925
32.44
26.527
23.003
18.83
Financial autonomy
50.329
52.324
58.932
62.552
65.972
68.448
73.012
72.084
73.498
Repayment capacity
8.574
6.648
4.785
None
None
None
2.259
6.085
None
Cash flow / Revenue
7.013%
8.454%
9.028%
None%
None%
None%
11.747%
3.122%
None%
Sector positioning
Debt ratio
18.832024
2022
2023
2024
Q1: 16.46
Med: 58.48
Q3: 154.77
Good
In 2024, the debt ratio of PHARMACIE DES TILLEULS (18.83) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.
Financial autonomy
73.5%2024
2022
2023
2024
Q1: 28.91%
Med: 49.95%
Q3: 69.47%
Excellent
In 2024, the financial autonomy of PHARMACIE DES TILLEULS (73.5%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.
Repayment capacity
6.08 years2023
2022
2023
Q1: 0.95 years
Med: 3.58 years
Q3: 7.48 years
Average+30 pts over 2 years
In 2023, the repayment capacity of PHARMACIE DES TILLEULS (6.08) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 249.70. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2024)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
249.698
Liquidity indicators evolution PHARMACIE DES TILLEULS
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2016
2017
2018
2019
2020
2021
2022
2023
2024
Liquidity ratio
240.932
223.309
191.802
227.858
260.842
284.453
375.024
266.307
249.698
Interest coverage
30.783
9.086
4.367
None
None
None
1.477
5.203
None
Sector positioning
Liquidity ratio
249.72024
2022
2023
2024
Q1: 129.46
Med: 182.14
Q3: 260.79
Good
In 2024, the liquidity ratio of PHARMACIE DES TILLEULS (249.70) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.
Interest coverage
5.2x2023
2022
2023
Q1: 0.38x
Med: 2.71x
Q3: 6.47x
Good+31 pts over 2 years
In 2023, the interest coverage of PHARMACIE DES TILLEULS (5.2x) ranks above the median of the sector. This ratio indicates how many times operating income covers interest expenses. This comfortable position offers an appreciable safety margin.
Working capital requirement (WCR) and payment terms
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.
Operating WCR (2024)
?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released Positive = financing needed
0 €
Customer credit (2024)
?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good 45-60j : Average > 60j : Long
0 j
Supplier credit (2024)
?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow
0 j
Inventory turnover (2024)
?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover
0 j
WCR and payment terms evolution PHARMACIE DES TILLEULS
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2016
2017
2018
2019
2020
2021
2022
2023
2024
Operating WCR
117 918 €
83 642 €
115 206 €
0 €
0 €
0 €
129 155 €
176 968 €
0 €
Inventory turnover (days)
23
22
22
0
0
0
14
17
0
Customer payment term (days)
3
3
3
0
0
0
12
1
0
Supplier payment term (days)
47
60
58
0
0
0
44
43
0
Positioning of PHARMACIE DES TILLEULS in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 225 transactions of similar company sales
in 2024,
the value of PHARMACIE DES TILLEULS is estimated at
1 239 392 €
(range 863 093€ - 1 854 202€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2024
225 transactions
863k€1239k€1854k€
1 239 392 €Range: 863 093€ - 1 854 202€
NAF 5 année 2024
Valuation method used
Net Income Multiple
88 777 €
×
14.0x
=1 239 393 €
Range: 863 093€ - 1 854 202€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 225 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare PHARMACIE DES TILLEULS with other companies in the same sector:
Frequently asked questions about PHARMACIE DES TILLEULS
What is the revenue of PHARMACIE DES TILLEULS ?
The revenue of PHARMACIE DES TILLEULS in 2023 is 2.7 M€.
Is PHARMACIE DES TILLEULS profitable?
Yes, PHARMACIE DES TILLEULS generated a net profit of 89 k€ in 2024.
Where is the headquarters of PHARMACIE DES TILLEULS ?
The headquarters of PHARMACIE DES TILLEULS is located in PONTACQ (64530), in the department Pyrenees-Atlantiques.
Where to find the tax return of PHARMACIE DES TILLEULS ?
The tax return of PHARMACIE DES TILLEULS is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does PHARMACIE DES TILLEULS operate?
PHARMACIE DES TILLEULS operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart